Fluoroquinolones, Sulfonamides and Trimethoprim
3rd Year MBBS • Infection and Inflammation • Pharmacology
Connect the major drug targets, antibacterial effects, clinical uses and important cautions for rapid revision.
1. THE TOPIC IN ONE CONNECTED FLOW
These antibacterial drugs act at two different essential bacterial processes. Fluoroquinolones disrupt bacterial DNA handling, while sulfonamides and trimethoprim interrupt folate metabolism. Their clinical usefulness depends on matching the drug’s target, spectrum, pharmacokinetics and adverse-effect profile to the infection being treated.
→
DNA gyrase / topoisomerase IV inhibition
→
abnormal DNA supercoiling and chromosome separation
→
failure of bacterial DNA replication
→
bactericidal, concentration-dependent effect.
→
trimethoprim blocks dihydrofolate reductase
→
sequential folate blockade
→
reduced tetrahydrofolate
→
impaired nucleic-acid precursor synthesis.
2. KEY CLINICAL CONNECTIONS
Levofloxacin / moxifloxacin → improved pneumococcal activity → respiratory usefulness.
Moxifloxacin → substantial non-renal elimination → lower urinary exposure → not preferred when high urinary concentrations are required.
Good oral absorption + tissue penetration → useful systemic exposure after oral administration.
Higher exposure relative to bacterial susceptibility → greater killing → concentration-dependent antibacterial effect.
Fluoroquinolones → tendon, peripheral nerve and cardiac repolarization toxicity → important clinical caution.
Sulfonamides → oxidative stress in G6PD deficiency or bilirubin displacement in neonates → hemolysis or kernicterus risk.
Calcium / magnesium / aluminum / iron → chelation of oral fluoroquinolone → reduced absorption and antibacterial exposure.
Sulfonamide + phenytoin → reduced clearance / increased active exposure → increased risk of phenytoin toxicity.
3. AIM HIGH-YIELD INTEGRATION REVIEW
Sulfonamides inhibit dihydropteroate synthase, whereas trimethoprim inhibits dihydrofolate reductase. Fluoroquinolones act on DNA gyrase/topoisomerase IV rather than the folate pathway.
